Evolus Inc. (EOLS)

27.38
NASDAQ : Health Technology
Prev Close 27.38
Day Low/High 0.00 / 0.00
52 Wk Low/High 6.75 / 39.50
Avg Volume 845.70K
Exchange NASDAQ
Shares Outstanding 27.27M
Market Cap 746.79M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Shares of Botox maker Allergan slipped after a billionaire hedge-fund manager challenges the company's management.

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Evolus surges Monday after the U.S. Food and Drug Administration approves the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.

Evolus Reaches Analyst Target Price

Evolus Reaches Analyst Target Price

In recent trading, shares of Evolus Inc have crossed above the average analyst 12-month target price of $28.00, changing hands for $29.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

DocuSign, DexCom, Skechers USA: 'Mad Money' Lightning Round

Jim Cramer weighs in on DocuSign, DexCom, Skechers USA, Campbell Soup, Evolus, Zscaler, Lockheed Martin and more.

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Revaluing Entertainment Companies: Cramer's 'Mad Money' Recap (Thursday 6/14/18)

Jim Cramer says there's the market that's about entertainment and anything that delivers entertainment to you. And then there's everything else.

Evolus Reaches Analyst Target Price

In recent trading, shares of Evolus Inc have crossed above the average analyst 12-month target price of $22.50, changing hands for $23.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

Here's what you need to know now for Thursday, May 17.

Allergan's Meury Talks Market Expansion in Aesthetics

Allergan's Meury Talks Market Expansion in Aesthetics

The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.

INVESTOR ALERT: Investigation On Behalf Of Evolus Investors Announced By Holzer & Holzer

INVESTOR ALERT: Investigation On Behalf Of Evolus Investors Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS) complied with the federal securities laws.

Evolus Phase III European - Canadian Head-to-Head Trial Of PrabotulinumtoxinA Compared To Botox® Meets Primary Endpoint

Evolus Phase III European - Canadian Head-to-Head Trial Of PrabotulinumtoxinA Compared To Botox® Meets Primary Endpoint

Results presented today at 2018 Aesthetic and Anti-Aging Medicine World Congress (AMWC)

Trimming Allergan

This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival

Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

The chief commercial officer of the Dublin drugmaker describes the long-term outlook for the medical aesthetics business as 'exceptional.'